30 Apr 2019
The board has proposed a rights issue to start addressing large markets in diabetes and oncology care. We see signs of increased growth and news flow as supportive for the shares.
Read the full report (Swedish) here.
Wir verwenden Cookies, um Ihnen das bestmögliche Erlebnis unserer Website zu bieten Mehr Infos
Managing Partner
Telefon: +49 30 809 33 47-13
@
Telefon: +49 40 300 836-11
Telefon: +49 89 255 49 53-11
Telefon: +49 40 300 836-19
Partner
Telefon: +49 40 300 836-16
Telefon: +49 89 255 49 53-15
Telefon: +49 89 255 49 53-17
Telefon: +46 70 496 18 15
Director
Telefon: +46 73 850 35 59
Telefon: +44 20 80176020
Telefon: +45 4199 8252
Telefon: +45 4199 8251
Telefon: +45 2634 9031
10707 Berlin
Telefon: +49 30 809 334 70
Office Management
Telefon: +49 30 809 33 47-10
Telefon: +49 30 809 33 47-12
Telefon: +49 30 809 33 47-25
Vice President
Telefon: +49 30 809 33 47-20
1253 Copenhagen K
Telefon: +45 3945 0010
20354 Hamburg
Telefon: +49 40 300 83 60
Office Management & Buchhaltung
Telefon: +49 40 300 836 10
PR, Marketing & Business Development Manager
Telefon: +49 40 300 836 18
Telefon: +49 40 300 836-24
London WC2N 6DF
Telefon: +44 20 8017 6020
Associate
Telefon: +44 77 1347-8286
80539 München
Telefon: +49 89 255 495 30
Office Management & HR
Telefon: +49 89 255 495 310
Telefon: +49 89 255 49 53-12
111 45 Stockholm
Telefon: +46 8 684 439 00
Strategic Business Manager
Telefon: +46 73 382 10 82
Office Manager
Telefon: +46 70 246 99 88
Director ECM
Telefon: +46 70 434 85 03
Head of Equity Research
Telefon: +46 76 235 03 20
Senior Equity Analyst
Telefon: +46 70 434 90 03
Associate Equity Analyst
Telefon: +46 73 539 66 99
IT&Telecom Expert
Senior Advisor Life Science
Telefon: +46 73 312 44 90
